/PRNewswire/ Engimmune Therapeutics AG ("Engimmune"), a world-class developer of soluble T-cell receptor drugs ( TCRs ) to treat solid tumours, is pleased.
Dr. Søren Mouritsen, co-founder of Engimmune, steps down as Chief Executive Officer in planned transitionBASEL, Switzerland, April 19, 2023 /PRNewswire/ Engimmune Therapeutics AG ("Engimmune")
/PRNewswire/ Engimmune Therapeutics AG ("Engimmune"), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, announced today the.